Cost-per-response of Acthar Gel versus standard of care for the treatment of noninfectious keratitis: a United States healthcare perspective

Aim: Persistently active noninfectious keratitis can lead to permanent corneal damage and loss of vision. Given the limited treatment options, Acthar Gel, a US FDA-approved treatment for ocular inflammatory conditions, can be a potential therapy. This study evaluated the cost-per-response of Actha...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jas Bindra, Ishveen Chopra, Kyle Hayes, John Niewoehner, Mary Panaccio, George J Wan
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Becaris Publishing Limited 2025-07-01
coleção:	Journal of Comparative Effectiveness Research
Assuntos:	acthar gel cost per response eye disorders noninfectious keratitis repository corticotropin injection
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!